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ABSTRACT 
 
Objective: To estimate the patient-specific risk of preeclampsia (PE) at 31-34 weeks’ 
gestation by a combination of maternal characteristics and medical history with multiple of 
the median (MoM) values of serum placental growth factor (PLGF) and serum soluble 
fms-like tyrosine kinase-1 (sFLT-1) and compare the performance of screening to that 
achieved by the sFLT-1 to PLGF ratio. 
 
Methods: This was a prospective observational study in women attending for a 
third-trimester ultrasound scan at 31-34 weeks as part of routine pregnancy care. We 
estimated the performance of screening of PE with delivery within four weeks of 
assessment (PE at <4 weeks) and PE from four weeks after assessment and up to 40 
weeks’ gestation (PE at 4w-40GW) in screening by the sFLT-1 to PLGF ratio and by a 
method utilizing Bayes theorem to combine maternal factors and MoM values of sFLT-1 
and PLGF. The significance of difference in performance of screening between the 
method utilising Bayes theorem and that of the sFLT-1 to PLGF ratio was assessed by 
comparison of the areas under the receiver operating characteristic curves (AUROC). 
 
Results: The study population of 8,063 singleton pregnancies included 231 (2.9%) that 
subsequently developed PE. In the prediction of delivery with PE at <4 weeks the 
performance of the method utilising Bayes theorem was similar to that of the sFLT-1 to 
PLGF (AUROC: 0.987, 95%CI 0.979-0.995 vs. 0.988, 95%CI: 0.981-0.994; p=0.961). 
and at fixed screen positive rate (SPR) of 3.9% the detection rate (DR) was 87.1% for 
both methods. In contrast, the performance of screening for delivery with PE at 4w-40GW 
was better with the method utilising Bayes theorem than with the sFLT-1 to PLGF ratio 
(AUROC: 0.884, 95%CI 0.854-0.914 vs. 0.818, 95%CI: 0.775-0.860 ; p<0.0001) and at 
total fixed SPR of 25.7% the DRs were 84.4% vs. 73.0%. 
 
Conclusion: At 31-34 weeks’ gestation the performance of screening for PE at <4 weeks 
from assessment by the method utilising Bayes theorem is similar to that of the sFLT-1 to 
PLGF ratio, but the former is superior to the latter in prediction of PE at >4 weeks. 
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Introduction 
 
In women with preeclampsia (PE) the maternal serum concentration of the angiogenic 
placental growth factor (PLGF) is decreased and the level of the anti-angiogenic soluble 
fms-like tyrosine kinase 1 (sFLT-1) is increased.1,2 There is also evidence that the altered 
levels of PLGF and sFLT-1 precede the clinical onset of the disease and measurement of 
these biomarkers can be used for the prediction of PE.2-9 Our approach to screening for 
PE is to use Bayes theorem to derive the posterior risk by combining the prior risk from 
maternal characteristics and medical history with multiple of the median (MoM) values of 
biomarkers.8,10-15 Others, advocate the use of the simpler sFLT-1 to PLGF ratio.4,9 
 
We have recently proposed an approach for stratification of pregnancies into high-, 
intermediate- and low-risk management groups based on the results of assessment of 
risk for PE at 32 weeks’ gestation (Figure 1).16 The high-risk group would require 
intensive monitoring from the time of the initial assessment and up to 40 weeks’ gestation, 
the intermediate-risk group would require reassessment four weeks after the initial 
assessment or intensive monitoring starting from four weeks and up to 40 weeks’ 
gestation and the low-risk group would be reassessed only at 40 weeks’ gestation. The 
performance of screening at 32 weeks is poor for prediction of PE at >40 weeks’ 
gestation 8 and it would therefore be necessary to reassess all remaining pregnancies at 
40 weeks to decide the best time and method of delivery.       
 
The objective of this study is to compare the performance of screening by the method 
utilising Bayes theorem to that of the sFLT-1 to PLGF ratio in the prediction of delivery 
with PE at <4 weeks from assessment (PE at <4 weeks) and delivery with PE at four 
weeks from assessment and up to 40 weeks’ gestation (4w-40GW).  
 
 
Methods 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for a 32 week routine hospital visit at King’s College 
Hospital, London or Medway Maritime Hospital, Gillingham, UK between March 2012 and 
January 2014. This visit included recording of maternal demographic characteristics and 
medical history, ultrasound examination for fetal anatomy and growth, and measurement 
of serum concentration of PLGF and sFLT-1 in pg/mL by an automated biochemical 
analyzer within 10 minutes of blood sampling and results being available 30 minutes later 
(Cobas e411 system, Roche Diagnostics, Penzberg, Germany). Gestational age was 
determined by the measurement of fetal crown-rump length at 11-13 weeks or the fetal 
head circumference at 19-24 weeks.17,18  
 
The women gave written informed consent to participate in the study, which was 
approved by the NHS Research Ethics Committee. The inclusion criteria for this study 
were singleton pregnancies examined at 31+0-33+6 weeks’ gestation and delivering a 
non-malformed live birth or stillbirth at >31 weeks’ gestation. We excluded pregnancies 
with aneuploidies and major fetal abnormalities. The study population was included in our 
previous report.8 
 
Data on pregnancy outcome were collected from the hospital maternity records or the 
general medical practitioners of the women. The obstetric records of all women with 
pre-existing or pregnancy associated hypertension were examined to determine if the 
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condition was PE, as defined by the International Society for the Study of Hypertension in 
Pregnancy.19  
 
Statistical analysis 
 
Patient-specific risks of delivery with PE at <4 weeks from assessment and at <40 weeks’ 
gestation were calculated using the competing risks model to combine the prior risk for 
PE from maternal characteristics and medical history with MoM values of PLGF and 
sFLT-1.8,10-15 Pregnancies were allocated to the high-risk group if their risk for PE at <4 
weeks was above a specific high-risk threshold and they were allocated to the low-risk 
group if their risk for PE at <40 weeks’ gestation was below a specified low-risk threshold. 
Otherwise, they were allocated to the intermediate risk group.16 Different risk cut-offs 
were used to vary the proportion of the population stratified into each risk category and 
performance was assessed in terms of the distribution of pregnancy outcomes by risk 
group. In order to compare stratification based on risks utilising Bayes theorem with that 
based on sFLT-1 to PLGF ratios we computed the cut-offs for stratification on the basis of 
ratios that would give the same proportions in the high-, intermediate- and low-risk groups 
as those obtained by the risks. We also examined the performance of sFLT-1/PLGF >38, 
because this ratio was previously reported as being useful in the prediction of PE at <4 
weeks in high-risk pregnancies.9  
 
The significance of difference in performance between the method utilising Bayes 
theorem and that of the sFLT-1 to PLGF ratio was assessed by comparison of the areas 
under the receiver operating characteristic curves (AUROC).20  
 
The statistical software package R was used for data analyses.21 
 
 
Results 
 
The study population of 8,063 singleton pregnancies included 231 (2.9%) that 
subsequently developed PE. Maternal and pregnancy characteristics of the study 
population are summarized in Table 1.  
 
Comparison of screening performance 
 
The ROC curves for performance of screening for PE at <4 weeks and PE at 4w-40GW 
by the method utilising Bayes theorem and that of the sFLT-1 to PLGF ratio are shown in 
Figure 2. There was no significant difference in performance of screening for PE at <4 
weeks between the method utilising Bayes theorem and that of the sFLT-1 to PLGF ratio 
of (AUROC: 0.987, 95%CI 0.979-0.995 vs. 0.988, 95%CI: 0.981-0.994; p=0.961). In 
contrast, the performance of screening for PE at 4w-40GW by utilising Bayes theorem 
was significantly better than that of the sFLT-1 to PLGF ratio (AUROC: 0.884, 95%CI 
0.854-0.914 vs. 0.818, 95%CI: 0.775-0.860 ; p<0.0001). 
 
Performance of SFLT-1 to PLGF ratio >38 
 
The sFLT-1 to PLGF ratio was >38 in 1.9% of the population and this group contained 
75.9% of pregnancies with PE at <4 weeks and 24.1% of those with PE at 4w-40GW 
(Table 2). In the method utilising Bayes theorem, the risk cut-off for PE at <4 weeks 
allocating 2.0% of pregnancies to the high-risk group was 1 in 8.5 and the 2.0% of 
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pregnancies selected by this method contained 80.6% of pregnancies with PE at <4 
weeks and 29.1% of those with PE at 4w-40GW. 
 
Stratification of the population into high-, intermediate- and low-risk groups   
 
The allocation of pregnancies to risk group by pregnancy outcome is given in Table 2.  
 
In the study population there were 29 pregnancies that were delivered with PE at <4 
weeks. At risk cut-off of 1 in 3 for PE at <4 weeks, 74.2% of pregnancies with PE at <4 
weeks were allocated to the high-risk group which comprised of 1.2% of all pregnancies. 
The proportion of all pregnancies and those with PE at <4 weeks allocated to the 
high-risk group increased from 1.2 and 74.2%, respectively, if the risk cut-off was 1 in 3 to 
5.9 and 93.5% if the risk cut-off was 1 in 150.  
 
The cut-off in sFLT-1 to PLGF ratio that would be equivalent to a risk cut-off of 1 in 3 in 
allocating 1.2% of pregnancies to the high-risk group was 56.88; at this cut-off, 67.7% of 
pregnancies with PE at <4 weeks were allocated to the high-risk group. The cut-off in 
sFLT-1 to PLGF ratio that would be equivalent to a risk cut-off of 1 in 150 in allocating 
5.9% of pregnancies to the high-risk group was 16.67; at this cut-off 100% of pregnancies 
with PE at <4 weeks were allocated to the high-risk group. For the same proportion of all 
pregnancies allocated to the high-risk group by the method utilizing Bayes theorem and 
the one by the sFLT-1 to PLGF ratio, the proportion of pregnancies with PE at <4 weeks 
contained within this group was similar (proportion of the population 1.2%: proportion of 
PE at <4 weeks 74.2% vs 67.7%; population 2.1%: PE 80.6% vs 77.4%; population 3.9%: 
PE 87.1% for both; population 5.0%: PE 87.1% vs 90.3%; population 5.9%: PE 93.5% vs 
100%). 
 
In the study population there were 141 pregnancies that delivered with PE at 4w-40GW. 
The allocation of these cases into the high-, intermediate- and low-risk groups is shown in 
Table 2. For example, the high-risk group defined by a risk cut-off of 1 in 50 for PE at <4 
weeks constituted 3.9% of the population and contained 44.0% (62/141) of pregnancies 
with PE at 4w-40GW. Using this risk cut-off of 1 in 50 for PE at <4 weeks and a risk cut-off 
of 1 in 150 for PE at <40 weeks’ gestation, 29.1% of pregnancies were allocated to the 
intermediate-risk group which contained 43.3% (61/141) of pregnancies with PE at 
4w-40GW. Consequently, for these particular risk cut-offs, 33.0% of pregnancies were 
allocated to the high- or intermediate-risk group and the combination of these groups 
contained a total of 83.3% (123/141) of pregnancies with PE at 4w-40GW. 
 
The cut-off in sFLT-1 to PLGF ratio that would be equivalent to a risk cut-off of 1 in 50 for 
PE at <4 weeks allocating 3.9% of pregnancies to the high-risk group was 22.38; at this 
cut-off, 40.4% of pregnancies with PE at 4w-40GW were allocated to the high-risk group, 
compared to 44.0% when the group of 3.9% of pregnancies was selected by the method 
utilizing Bayes theorem. The combination of risk cut-off of 1 in 50 for PE at <4 weeks 
(sFLT-1 to PLGF ratio 22.38) and risk cut-off of 1 in 150 for PE at <40 weeks’ gestation 
(sFLT-1 to PLGF ratio 4.35) allocated 29.1% of pregnancies to the intermediate-risk 
group; this group contained 41.1% of pregnancies with PE at 4w-40GW when selection of 
the group was by sFLT-1 to PLGF ratio, compared to 43.3% with selection by the method 
utilizing Bayes theorem. Consequently, for these particular risk or ratio cut-offs, 33.0% of 
pregnancies were allocated to the high- or intermediate-risk group and the combination of 
these groups contained a total of 81.5% of pregnancies with PE at 4w-40GW when the 
groups were selected by sFLT-1 to PLGF ratio, compared to 83.3% with selection by the 
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method utilizing Bayes theorem. 
 
 
Discussion 
 
Main findings 
 
The study has demonstrated how assessment of risk for PE at 31-34 weeks’ gestation 
can be used to stratify the population into high- intermediate- and low-risk groups. Two 
approaches were applied to achieve such stratification and their performance was 
compared. The first approach utilised Bayes theorem to combine maternal factors with 
MoM values of sFLT-1 and PLGF and derive patient-specific risks and the second 
approach used a simple division of the measured concentration of sFLT-1 by that of 
PLGF. The advantage of the ratio is simplicity in clinical practice. However, such 
approach does not take into account the prior risk of the individual patient in the study 
population and ignores the effects of maternal characteristics on the measured serum 
concentrations and their interrelations in both normal and pathological pregnancies.10,14,15 
 
We found that the performance of screening for PE at <4 weeks of assessment was 
similar by the two methods, but the method utilising Bayes theorem was superior to that 
of the sFLT-1 to PLGF ratio in prediction of PE at >4 weeks. These findings confirm that 
the sFLT-1 to PLGF ratio is a very strong predictor of imminent PE and the contribution of 
the prior risk from maternal factors in identifying the high-risk group is relatively small. 
With increasing intervals between sampling and development of PE the contribution of 
maternal factors in prediction of PE becomes more apparent as the contribution of the 
sFLT-1 to PLGF ratio becomes weaker. 
 
The proportion of the population stratified into high- intermediate- and low-risk groups and 
the proportion of each strata developing PE with delivery at <4 weeks, at 4w-40GW and 
at >40GW would inevitably depend on the risk cut-offs used for defining the groups. In 
order to compare stratification based on risks utilising Bayes theorem with that based on 
sFLT-1 to PLGF ratios we computed the cut-offs for stratification on the basis of ratios that 
would give the same proportions in the high-, intermediate- and low-risk groups as those 
obtained by the risks. The cut-offs in the sFLT-1 to PLGF ratio for identifying the high-risk 
group for delivery with PE at <4 weeks ranged from 56.88 to 16.67 with respective 
proportions of the population allocated to the high-risk group ranging from 1.2 to 5.9% 
and proportion of cases with PE at <4 weeks contained in this group varying from 
67.7-100%. A previous study advocated the use of the specific ratio of >38 to identify a 
group at high-risk of developing PE within the subsequent four weeks;9 in this study, 2.0% 
of the population fulfilled this criterion and this group contained 77.4% of pregnancies 
with PE at <4 weeks and 24.1% of those with PE at 4w-40GW 
 
Strengths and limitations 
 
The strengths of this study are first, examination of a large population of pregnant women 
attending for routine care in a gestational age range which is widely used for assessment 
of fetal growth and wellbeing, second, recording of data on maternal characteristics and 
medical history to define the prior risk, third, use of automated machines to provide 
accurate measurement within 40 minutes of sampling of maternal serum concentration of 
PLGF and sFLT-1, fourth, expression of the values of the biomarkers as MoMs after 
adjustment for factors that affect the measurements and use of Bayes theorem to 
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combine the prior risk from maternal factors with biomarkers to estimate patient-specific 
risks and the performance of screening for PE delivering at different stages of pregnancy 
and fifth, direct comparison of the performance of screening for PE by a method utilizing 
Bayes theorem to that of the sFLT-1 to PLGF ratio. 
 
A limitation of the study is that fitting of the risk model 8 and development and assessment 
of risk stratification were on the same data, which induces a degree of optimistic bias into 
the results. However, our risk model4 is a parsimonious one with just two parameters for 
the mean log MoM value for each of the markers and a pooled estimate of an assumed 
common covariance matrix and this limits the degree of bias induced. Nevertheless, 
prospective evaluation using an independent test data set is needed to validate the 
results. 
 
Comparison with previous studies 
 
Our findings are compatible with those of a previous screening study for PE at 30-34 
weeks’ gestation which included 118 cases of PE and 3,734 unaffected pregnancies; in 
the cases of PE the sFLT-1 MoM to PLGF MoM ratio was increased and the deviation 
from normal was inversely related to the interval between sampling and the gestational 
age at delivery.7 Our findings are also compatible with those of previous studies 
investigating high-risk pregnancies which reported that the sFlt-1 to PLGF ratio is highly 
accurate in identifying the subgroup that will develop severe PE requiring delivery within 
the subsequent few weeks.3-6,9   
 
A study investigating serum PLGF at 11-13, 19-25, 30-34 and 35-37 weeks’ gestation, 
demonstrated that in pregnancies that develop PE, serum PLGF in all four gestational 
age groups was decreased, but the separation in MoM values from normal was greater 
when the interval between sampling the development of PE was closer; the performance 
of screening for PE at <37 weeks’ gestation was superior with screening at 32 than at 22 
or 12 weeks and the performance of screening for PE at >37 weeks was superior with 
screening at 36 weeks than at earlier gestations.22 A similar study demonstrated that in 
pregnancies that develop PE, serum sFLT-1 is increased and the separation in MoM 
values from normal was greater when the interval between sampling the development of 
PE was closer; however, unlike PLGF, sFLT-1 at 11-13 weeks was not a useful marker of 
PE.23 
 
Clinical implications of the study 
 
In the traditional approach to prenatal care, screening and diagnosis of PE is based on 
the demonstration of elevated blood pressure and proteinuria during a routine clinical visit 
in the late second- or third-trimester of pregnancy.  
 
In a proposed new pyramid of pregnancy care, the timing and content of clinical visits 
should be defined by the patient-specific risk of developing PE.25 This study provides the 
framework for subsequent management of pregnancies based on the results of screening 
by maternal factors and the measurements of serum sFLT-1 and PLGF at 30-34 weeks’ 
gestation. A small high-risk group can be monitored by measurement of blood pressure 
and urinalysis at least on a weekly basis, a bigger intermediate-risk group would either be 
reassessed in four weeks or will undergo intensive monitoring from four weeks after the 
initial assessment, whereas patients in the large low-risk group can be reassured that 
development of PE before 40 weeks is very unlikely. 
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The best approach for stratification of risks for development of PE is the one that takes 
into account the prior risk of the individual patient based on maternal characteristics and 
medical history and defines the posterior risk by adjusting the measured serum 
concentrations of sFLT-1 and PLGF for those maternal characteristics that affect these 
measurements. 10,14,15 This approach also allows incorporation into the risk algorithm of 
additional potentially useful biomarkers, such as uterine artery pulsatility index and mean 
arterial pressure.8 The alternative approach for allocation of patients into management 
groups is the simple ratio of the measured concentrations of sFL-1 and PLGF; this 
appears to be equally good to that utilizing Bayes theorem in identifying the group at 
high-risk of developing PE at <4 weeks from assessment. However, in this respect the 
best ratio is not >38,9 but varies according to the desired proportion of the population 
allocated into the different management groups. The method utilizing Bayes theorem is 
superior to the ratio in identifying pregnancies at high-risk of developing PE at >4 weeks 
from assessment. 
 
The cut-offs in risks or sFLT-1 to PLGF ratios to define the proportion of the population 
stratified into each of the three management groups and the protocols for such 
management will inevitably vary according to local preferences and health economic 
considerations. Future studies will examine whether the implementation of such protocols 
could improve perinatal outcome. 
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Figure legends 
 
Figure 1. Stratification of pregnancies into high-, intermediate- and low-risk management 
groups based on screening for preeclampsia at 31-34 weeks’ gestation. The high-risk 
group would require intensive monitoring from the time of the initial assessment and up to 
40 weeks’ gestation, the intermediate-risk group would require intensive monitoring 
starting from four weeks after the initial assessment and up to 40 weeks’ gestation and 
the low-risk group would be reassessed only at 40 weeks’ gestation.  
 
Figure 2. Receiver operating characteristic curves for prediction of preeclampsia (PE) 
within four weeks of assessment (left) and PE from four weeks after assessment and up to 
40 weeks’ gestation (right) by a method utilising Bayes theorem (red line) and by the 
sFLT-1 to PLGF ratio (blue line). 
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Table 1. Maternal and pregnancy characteristics in pregnancies that developed 
preeclampsia (PE) within four weeks from assessment, at four weeks from assessment 
and up to 40 weeks’ gestation and at >40 weeks’ gestation, compared with pregnancies 
that remained normotensive. 
 
Maternal characteristics 
Preeclampsia 
None 
(n=7,832) 
<4 weeks 
(n=29) 
4 w-40GW 
(n=141) 
>40GW 
(n=61) 
Age, median (IQR) 31.0 (26.7-34.7) 31.0 (26.4-34.0) 31.7 (27.5-35.2) 31.0 (24.9-34.8) 
Weight, median (IQR) 67.3 (59.5-78.0) 70.4 (60.0-86.0) 76.0 (64.5-89.9) 69.0 (61.0-84.8) 
Height, median (IQR) 1.65 (1.60-1.69) 1.60 (1.58-1.65) 1.65 (1.60-1.69) 1.64 (1.60-1.69) 
Racial origin     
     Caucasian, n (%) 5880 (75.1) 19 (65.5) 80 (56.7) 41 (67.2) 
     Afro-Caribbean, n (%) 1339 (17.1) 8 (27.6) 50 (35.5) * 17 (27.9) 
     South Asian, n (%) 295 (3.8) 2 (6.9) 6 (4.3) 2 (3.3) 
     East Asian, n (%) 145 (1.9) 0 3 (2.1) 1 (1.6) 
     Mixed, n (%) 173 (2.2) 0 2 (1.4) 0 (0.0) 
Method of conception     
     Spontaneous, n (%) 7570 (96.7) 27 (93.1) 136 (96.5) 59 (96.7) 
     Assisted conception, n (%) 262 (3.3) 2 (6.9) 5 (3.5) 2 (3.3) 
Cigarette smoking, n (%) 790 (10.1) 1 (3.4) 8 (5.7) 4 (6.6) 
Chronic hypertension, n (%) 87 (1.1) 6 (20.7) 23 (16.3) 3 (4.9) 
SLE / APS, n (%) 14 (0.2) 0 0 0 
Diabetes mellitus, n (%) 76 (1.0) 0 3 (2.1) 0 
Parity     
     Nulliparous, n (%) 3839 (49.0) 18 (62.1)  68 (48.2) 48 (78.7) 
     Parous no previous PE, n (%) 3726 (47.6) 8 (27.6) 42 (29.8) 12 (19.7) 
     Parous previous PE, n (%) 267 (3.4) 3 (10.3) 31 (22.0) 1 (1.6) 
Family history of PE, n (%) 234 (3.0) 1 (3.4) 6 (4.3) 2 (3.3) 
Inter-pregnancy interval, median (IQR)* 3.1 (2.1-5.1) 7.1 (4.2-7.9) 3.6 (2.4-5.3) 6.5 (2.9-8.2) 
 
* Inter-pregnancy interval reported for parous women 
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Table 2: Stratification of risk for preeclampsia. The numbers in the grey bands represent the high-risk group and those in the white bands the 
intermediate-risk group. The cut-offs are given as risks estimated with the use of Bayes theorem to combine maternal characteristics with MoM 
values of sFLT-1 and PLGF or as sFLT-1 to PLGF ratio. Numbers in parentheses are percentages with 95% confidence intervals. 
Risk cut off 
SFLT-1 / PLGF 
cut-off 
All pregnancies 
(n=8063) 
PE at <4 w (n=29) PE at 4 w to 40 GW (n=141) PE at >40 GW (n=61) 
Combined test SFLT/PLGF Combined test SFLT/PLGF Combined test SFLT/PLGF 
1 in 3 for PE <4 w 56.88 for PE <4 w 99 (1.2; 1.0, 1.5) 23 (74.2; 55.4, 88.1) 21 (67.7; 48.6, 83.3) 22 (15.6; 10, 22.7) 23 (16.3; 10.6, 23.5) 1 (1.6; 0.0, 8.7) 1 (1.6; 0.0, 8.7) 
1 in 50 for PE <40 GW 7.41 for PE <40 GW 1268 (15.6; 14.8, 16.4) 8 (25.8; 11.9, 44.6) 10 (32.3; 16.7, 51.4) 89 (63.1; 54.6, 71.1) 71 (50.4; 41.8, 58.9) 27 (43.5; 31.0, 56.7) 22 (35.5; 23.7, 48.7) 
1 in 100 for PE <40 GW 5.35 for PE <40 GW 1987 (24.4; 23.5, 25.4) 8 (25.8; 11.9, 44.6) 10 (32.3; 16.7, 51.4) 97 (68.8; 60.5, 76.3) 80 (56.7; 48.1, 65.0) 35 (56.5; 43.3, 69.0) 33 (53.2; 40.1, 66.0) 
1 in 150 for PE <40 GW 4.35 for PE <40 GW 2577 (31.7; 30.7, 32.7) 8 (25.8; 11.9, 44.6) 10 (32.3; 16.7, 51.4) 101 (71.6; 63.4, 78.9) 92 (65.2; 56.8, 73.1) 42 (67.7; 54.7, 79.1) 36 (58.1; 44.8, 70.5) 
1 in 200 for PE <40 GW 3.73 for PE <40 GW 3085 (38.0; 36.9, 39.0) 8 (25.8; 11.9, 44.6) 10 (32.3; 16.7, 51.4) 106 (75.2; 67.2, 82.1) 95 (67.4; 59.0, 75.0) 46 (74.2; 61.5, 84.5) 39 (62.9; 49.7, 74.8) 
1 in 10 for PE <4 w 35.63 for PE <4 w 170 (2.1; 1.8, 2.4) 25 (80.6; 62.5, 92.5) 24 (77.4; 58.9, 90.4) 42 (29.8; 22.4, 38.1) 36 (25.5; 18.6, 33.6) 2 (3.2; 0.4, 11.2) 4 (6.5; 1.8, 15.7) 
1 in 50 for PE <40 GW 7.41 for PE <40 GW 1197 (14.7; 14, 15.5) 6 (19.4; 7.5, 37.5) 7 (22.6; 9.6, 41.1) 69 (48.9; 40.4, 57.5) 58 (41.1; 32.9, 49.7) 26 (41.9; 29.5, 55.2) 19 (30.6; 19.6, 43.7) 
1 in 100 for PE <40 GW 5.35 for PE <40 GW 1916 (23.6; 22.7, 24.5) 6 (19.4; 7.5, 37.5) 7 (22.6; 9.6, 41.1) 77 (54.6; 46.0, 63.0) 67 (47.5; 39.1, 56.1) 34 (54.8; 41.7, 67.5) 30 (48.4; 35.5, 61.4) 
1 in 150 for PE <40 GW 4.35 for PE <40 GW 2506 (30.8; 29.8, 31.8) 6 (19.4; 7.5, 37.5) 7 (22.6; 9.6, 41.1) 81 (57.4; 48.8, 65.7) 79 (56.0; 47.4, 64.4) 41 (66.1; 53.0, 77.7) 33 (53.2; 40.1, 66.0) 
1 in 200 for PE <40 GW 3.73 for PE <40 GW 3014 (37.1; 36.0, 38.1) 6 (19.4; 7.5, 37.5) 7 (22.6; 9.6, 41.1) 86 (61.0; 52.4, 69.1) 82 (58.2; 49.6, 66.4) 45 (72.6; 59.8, 83.1) 36 (58.1; 44.8, 70.5) 
1 in 50 for PE <4 w 22.38 for PE <4 w 314 (3.9; 3.5, 4.3) 27 (87.1; 70.2, 96.4) 27 (87.1; 70.2, 96.4) 62 (44.0; 35.6, 52.6) 57 (40.4; 32.3, 49.0) 6 (9.7; 3.6, 19.9) 6 (9.7; 3.6, 19.9) 
1 in 50 for PE <40 GW 7.41 for PE <40 GW 1053 (13.0; 12.2, 13.7) 4 (12.9; 3.6, 29.8) 4 (12.9; 3.6, 29.8) 49 (34.8; 26.9, 43.2) 37 (26.2; 19.2, 34.3) 22 (35.5; 23.7, 48.7) 17 (27.4; 16.9, 40.2) 
1 in 100 for PE <40 GW 5.35 for PE <40 GW 1772 (21.8; 20.9, 22.7) 4 (12.9; 3.6, 29.8) 4 (12.9; 3.6, 29.8) 57 (40.4; 32.3, 49.0) 46 (32.6; 25.0, 41.0) 30 (48.4; 35.5, 61.4) 28 (45.2; 32.5, 58.3) 
1 in 150 for PE <40 GW 4.35 for PE <40 GW 2362 (29.1; 28.1, 30.1) 4 (12.9; 3.6, 29.8) 4 (12.9; 3.6, 29.8) 61 (43.3; 35.0, 51.9) 58 (41.1; 32.9, 49.7) 37 (59.7; 46.4, 71.9) 31 (50.0; 37.0, 63.0) 
1 in 200 for PE <40 GW 3.73 for PE <40 GW 2870 (35.3; 34.3, 36.4) 4 (12.9; 3.6, 29.8) 4 (12.9; 3.6, 29.8) 66 (46.8; 38.4, 55.4) 61 (43.3; 35.0, 51.9) 41 (66.1; 53.0, 77.7) 34 (54.8; 41.7, 67.5) 
1 in 100 for PE <4 w 18.59 for PE <4 w 406 (5.0; 4.5, 5.5) 27 (87.1; 70.2, 96.4) 28 (90.3; 74.2, 98) 73 (51.8; 43.2, 60.3) 63 (44.7; 36.3, 53.3) 10 (16.1; 8.0, 27.7) 7 (11.3; 4.7, 21.9) 
1 in 50 for PE <40 GW 7.41 for PE <40 GW 961 (11.8; 11.1, 12.5) 4 (12.9; 3.6, 29.8) 3 (9.7; 2.0, 25.8) 38 (27.0; 19.8, 35.1) 31 (22.0; 15.5, 29.7) 18 (29.0; 18.2, 41.9) 16 (25.8; 15.5, 38.5) 
1 in 100 for PE <40 GW 5.35 for PE <40 GW 1680 (20.7; 19.8, 21.6) 4 (12.9; 3.6, 29.8) 3 (9.7; 2.0, 25.8) 46 (32.6; 25.0, 41.0) 40 (28.4; 21.1, 36.6) 27 (43.5; 31, 56.7) 26 (41.9; 29.5, 55.2) 
1 in 150 for PE <40 GW 4.35 for PE <40 GW 2270 (27.9; 27.0, 28.9) 4 (12.9; 3.6, 29.8) 3 (9.7; 2.0, 25.8) 50 (35.5; 27.6, 44.0) 52 (36.9; 28.9, 45.4) 33 (53.2; 40.1, 66.0) 30 (48.4; 35.5, 61.4) 
1 in 200 for PE <40 GW 3.73 for PE <40 GW 2778 (34.2; 33.1, 35.2) 4 (12.9; 3.6, 29.8) 3 (9.7; 2.0, 25.8) 55 (39.0; 30.9, 47.6) 55 (39.0; 30.9, 47.6) 37 (59.7; 46.4, 71.9) 33 (53.2; 40.1, 66.0) 
1 in 150 for PE <4 w 16.67 for PE <4 w 476 (5.9; 5.4, 6.4) 29 (93.5; 78.6, 99.2) 31 (100; 88.8, 100) 80 (56.7; 48.1, 65.0) 65 (46.1; 37.7, 54.7) 12 (19.4; 10.4, 31.4) 10 (16.1; 8.0, 27.7) 
1 in 50 for PE <40 GW 7.41 for PE <40 GW 891 (11.0; 10.3, 11.7) 2 (6.5; 0.8, 21.4) 0 (0.0; 0.0, 11.2) 31 (22.0; 15.5, 29.7) 29 (20.6; 14.2, 28.2) 16 (25.8; 15.5, 38.5) 13 (21.0; 11.7, 33.2) 
1 in 100 for PE <40 GW 5.35 for PE <40 GW 1610 (19.8; 18.9, 20.7) 2 (6.5; 0.8, 21.4) 0 (0.0; 0.0, 11.2) 39 (27.7; 20.5, 35.8) 38 (27.0; 19.8, 35.1) 24 (38.7; 26.6, 51.9) 24 (38.7; 26.6, 51.9) 
1 in 150 for PE <40 GW 4.35 for PE <40 GW 2200 (27.1; 26.1, 28.0) 2 (6.5; 0.8, 21.4) 0 (0.0; 0.0, 11.2) 43 (30.5; 23.0, 38.8) 50 (35.5; 27.6, 44.0) 31 (50.0; 37.0, 63.0) 27 (43.5; 31, 56.7) 
1 in 200 for PE <40 GW 3.73 for PE <40 GW 2708 (33.3; 32.3, 34.4) 2 (6.5; 0.8, 21.4) 0 (0.0; 0.0, 11.2) 48 (34.0; 26.3, 42.5) 53 (37.6; 29.6, 46.1) 35; (56.5; 43.3, 69.0) 30 (48.4; 35.5, 61.4) 
         
1 in 8.5 for PE<4 SFLT-1 / PLGF >38 159 (2.0; 1.7, 2.3) 25 (80.6; 62.5, 92.5)  24 (77.4; 58.9, 90.4) 41 (29.1; 21.7, 37.3)  34 (24.1; 17.0, 31.2) 1 (1.6; 0, 8.7)  3 (4.8; 0.5, 10.2) 
